Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy

N.D. Oreshkova, L. Spel, R.P.M. Vloet, P.J. Wichgers Schreur, R.J.M. Moormann, M. Boes, J.A. Kortekaas

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)


Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8+ T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.
Original languageEnglish
Pages (from-to)9124-9127
JournalJournal of Virology
Issue number17
Publication statusPublished - 2015

Fingerprint Dive into the research topics of 'Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy'. Together they form a unique fingerprint.

  • Cite this